Based on the Sotera Health Co stock forecast from 3 analysts, the average analyst target price for Sotera Health Co is USD 15.50 over the next 12 months. Sotera Health Co’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Sotera Health Co is Neutral, which is based on 7 positive signals and 8 negative signals. At the last closing, Sotera Health Co’s stock price was USD 14.31. Sotera Health Co’s stock price has changed by -11.06% over the past week, -6.96% over the past month and +4.07% over the last year.
No recent analyst target price found for Sotera Health Co
No recent average analyst rating found for Sotera Health Co
Company Overview Sotera Health Co
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio. Read Less
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization ...Read More
Frequently Asked Questions About Sotera Health Co (SHC) Stock
Based on ratings from 3 analysts Sotera Health Co's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 2 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on SHC's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SHC is USD 15.50 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 13.
SHC stock's Price/Earning ratio is 113.29.
Our analysis grades SHC stock's Price / Earning ratio at F. This means that SHC stock's Price/Earning ratio is above 87% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this SHC may be a overvalued for its sector.
The last closing price of SHC's stock was USD 14.31.
The most recent market capitalization for SHC is USD 4.49B.
Based on targets from 3 analysts, the average taret price for SHC is projected at USD 15.50 over the next 12 months.
This means that SHC's stock price may go up by +8.32% over the next 12 months.
We can't find any ETFs which contains Sotera Health Co's stock.
As per our most recent records Sotera Health Co has 3,000 Employees.
Sotera Health Co's registered address is 9100 South Hills Boulevard, Broadview Heights, OH, United States, 44147.
You can get more information about it from Sotera Health Co's website at https://soterahealth.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Sotera Health Co (SHC) Stock
Based on ratings from 3 analysts Sotera Health Co's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 2 buy, sell and 2 hold ratings.
Unfortunately we do not have enough data on SHC's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for SHC is USD 15.50 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 13.
SHC stock's Price/Earning ratio is 113.29.
Our analysis grades SHC stock's Price / Earning ratio at F. This means that SHC stock's Price/Earning ratio is above 87% of the stocks in the Diagnostics & Research sector in the NSD exchange.
Based on this SHC may be a overvalued for its sector.
The last closing price of SHC's stock was USD 14.31.
The most recent market capitalization for SHC is USD 4.49B.
Based on targets from 3 analysts, the average taret price for SHC is projected at USD 15.50 over the next 12 months.
This means that SHC's stock price may go up by +8.32% over the next 12 months.
We can't find any ETFs which contains Sotera Health Co's stock.
As per our most recent records Sotera Health Co has 3,000 Employees.
Sotera Health Co's registered address is 9100 South Hills Boulevard, Broadview Heights, OH, United States, 44147.
You can get more information about it from Sotera Health Co's website at https://soterahealth.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SHC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
